Business
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif., July 16, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telang
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/151f163310c048cae1847a954f4dd5ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NcmBo5fIxwGPvqbj.KyjAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/151f163310c048cae1847a954f4dd5ee","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TdauDkx5JAhcnchm1LaYlw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/151f163310c048cae1847a954f4dd5ee","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., July 16, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia (A-T).","length":532,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "The completion of enrollment in our pivotal Phase 3 NEAT clinical trial evaluating eDSP for the treatment of A-T is a major milestone for Quince that places us one step closer to advancing a first-to-market treatment for this devasting disease. We are confident that we have executed a well-designed study with a high degree of scientific integrity and vigilant operational oversight. Quince remains on track to deliver topline results in the first quarter of 2026 and positive results will lead to an NDA submission in the second half of 2026."","length":639,"tagName":"p"},{"type":"text","content":"Key Phase 3 NEAT clinical trial enrollment highlights include:","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A total of 105 participants were enrolled, including 83 participants in the six to nine year-old primary analysis population and 22 participants aged 10 years or older.","length":168,"tagName":"...